Abstract
Background: Cockayne syndrome (CS) is a DNA repair disorder primarily associated with pathogenic variants in ERCC6 and ERCC8. As in other Mendelian disorders, there are a number of genetically unsolved CS cases. Methods: We ascertained five individuals with monoallelic pathogenic variants in MORC2, previously associated with three dominantly inherited phenotypes: an axonal form of Charcot-Marie-Tooth disease type 2Z; a syndrome of developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy; and a rare form of spinal muscular atrophy. Results: One of these individuals bore a strong phenotypic resemblance to CS. We then identified monoallelic pathogenic MORC2 variants in three of five genetically unsolved individuals with a clinical diagnosis of CS. In total, we identified eight individuals with MORC2-related disorder, four of whom had clinical features strongly suggestive of CS. Conclusions: Our findings indicate that some forms of MORC2-related disorder have phenotypic similarities to CS, including features of accelerated aging. Unlike classic DNA repair disorders, MORC2-related disorder does not appear to be associated with a defect in transcription-coupled nucleotide excision repair and follows a dominant pattern of inheritance with variants typically arising de novo. Such de novo pathogenic variants present particular challenges with regard to both initial gene discovery and diagnostic evaluations. MORC2 should be included in diagnostic genetic test panels targeting the evaluation of microcephaly and/or suspected DNA repair disorders. Future studies of MORC2 and its protein product, coupled with further phenotypic characterization, will help to optimize the diagnosis, understanding, and therapy of the associated disorders.
Original language | English (US) |
---|---|
Pages (from-to) | 79-86 |
Number of pages | 8 |
Journal | Pediatric Neurology |
Volume | 141 |
DOIs | |
State | Published - Apr 2023 |
Bibliographical note
Funding Information:We appreciate the participation of all the families included in this cohort. Amy & Friends Cockayne Syndrome and Trichothiodystrophy Support, and the clinical team at the National CS/TTD Service in London, United Kingdom, assisted with participant ascertainment. Jill Clayton-Smith, MD, FRCP (Manchester Centre for Genomic Medicine) contributed to the diagnostic evaluation of one of the participants. This study was supported by the National Initiative for Cockayne Syndrome (NICS), FDA CBER R01 FD007483, the Canadian Institutes of Health Research (Grant numbers 377869 and 426534), Compute Canada (www.computecanada.ca/), and the McGill University and Genome Quebec Innovation Center. G. Bernard has received the Clinical Research Scholar Junior 1 award from the Fonds de Recherche du Quebec – Santé (FRQS) (2012-2016), the New Investigator Salary Award from the CIHR (2017-2022), and the Clinical Research Scholar Senior award from the FRQS (2022-2025). A.F. Theil is supported by grants from European Research Council Advanced grant (340988) and Oncode Institute (partly financed by the Dutch Cancer Society).
Funding Information:
Conflicts of interest declaration: G. Bernard would like to disclose that she is/was a consultant for Passage Bio Inc (2020-2022) and Ionis (2019). She is/was a site investigator for the Alexander's disease trial of Ionis (2021 to now), Metachromatic leukodystrophy of Shire/Takeda (2020-2021), Krabbe and GM1 gene therapy trials of Passage Bio (2021-now), Passage Bio GM1 natural history study (2021-now), and Adrenoleukodystrophy/Hematopoietic stem cell transplantation natural history study of Bluebird Bio (2019) and a site subinvestigator for the MPS II gene therapy trial of Regenxbio (2021 to now). She has received unrestricted educational grants from Takeda (2021-2022). She serves on the Scientific Advisory Board of the Pelizaeus-Merzbacher Foundation and the Yaya Foundation Scientific and Clinical Advisory Council and is the Chair of the Medical and Scientific Advisory Board of the United Leukodystrophy Foundation. She is a member of the Vanishing White Matter Consortium and the H-ABC Clinical Advisory Board and the Chair of the POLR3-related (4H) Leukodystrophy Consortium. She is on the editorial boards of Neurology Genetics, Frontiers in Neurology – Neurogenetics, and Journal of Medical Genetics. P. B. Kang reports financial support was provided by National Initiative for Cockayne Syndrome. C. A. Pacak reports financial support was provided by US Food and Drug Administration. G. Bernard reports financial support was provided by Canadian Institutes of Health Research. The remaining authors declare that there are no conflicts of interests regarding the publication of this article.
Funding Information:
We appreciate the participation of all the families included in this cohort. Amy & Friends Cockayne Syndrome and Trichothiodystrophy Support, and the clinical team at the National CS /TTD Service in London, United Kingdom, assisted with participant ascertainment. Jill Clayton-Smith, MD, FRCP (Manchester Centre for Genomic Medicine) contributed to the diagnostic evaluation of one of the participants. This study was supported by the National Initiative for Cockayne Syndrome (NICS), FDA CBER R01 FD007483 , the Canadian Institutes of Health Research (Grant numbers 377869 and 426534 ), Compute Canada ( www.computecanada.ca/ ), and the McGill University and Genome Quebec Innovation Center. G. Bernard has received the Clinical Research Scholar Junior 1 award from the Fonds de Recherche du Quebec – Santé (FRQS) (2012-2016), the New Investigator Salary Award from the CIHR (2017-2022), and the Clinical Research Scholar Senior award from the FRQS (2022-2025). A.F. Theil is supported by grants from European Research Council Advanced grant ( 340988 ) and Oncode Institute (partly financed by the Dutch Cancer Society).
Publisher Copyright:
© 2023 The Author(s)
Keywords
- Cockayne syndrome
- DNA repair
- MORC2
- Microcephaly
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.